Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Incyte
Pharma
Incyte posts mixed Opzelura results in prurigo nodularis
As Incyte strives to push Opzelura into new dermatology indications, the company’s latest data drop in prurigo nodularis is a bit of a mixed bag.
Fraiser Kansteiner
Mar 10, 2025 11:23am
Incyte provides first guidance for JAK cream Opzelura
Feb 10, 2025 2:25pm
JPM25: Incyte plans to turn 'a lot of cards' in 2025, CEO says
Jan 22, 2025 2:38pm
Incyte's Monjuvi proves its worth in follicular lymphoma
Nov 25, 2024 3:20pm
For 2nd time in three months, Syndax wins FDA nod for a new drug
Nov 18, 2024 11:09am
AZ China fallout, Pfizer's $1B plan in China—Fierce Pharma Asia
Nov 8, 2024 8:54am
